Sustained Molecular Pathology Across Episodes and Remission in Major Depressive Disorder

Area of Science:

• Neuroscience
• Psychiatry
• Proteomics

Background:

• Major depressive disorder (MDD) is a significant mental illness causing widespread productivity loss.
• MDD patients frequently experience recurring episodes, increasing severity, reduced treatment efficacy, and shorter remission periods, suggesting underlying persistent pathology.

Purpose of the Study:

• To investigate trait and state progressive neuropathologies in MDD using proteomic analysis.
• To identify persistent molecular alterations in the subgenual anterior cingulate cortex (sACC) of MDD patients.

Main Methods:

• Mass spectrometry-based proteomics analyzed postmortem sACC samples from four MDD cohorts and one control cohort (n=3630 proteins).
• Statistical analyses were employed to examine proteomic differences related to MDD state, episode history, and persistent effects.
• Western blot validated key proteins involved in neurotransmission and synaptic function.

Main Results:

• Proteomic analysis revealed weak evidence for differences based on MDD state (depressed/remitted) or episode history.
• Significant persistent MDD effects were observed, impacting presynaptic neurotransmission, synaptic function, energy metabolism, and calcium homeostasis.
• Validated proteins included dihydropyrimidinase-related protein 1, synaptosomal-associated protein 29, and glutamate decarboxylase 1.

Conclusions:

• The study provides evidence for persistent molecular alterations in MDD, independent of current episode status or remission.
• No detectable progressive neuropathology was identified in the studied MDD cohorts.
• Findings highlight persistent changes in synaptic and neurotransmitter systems in MDD.